Dr. Reddy’s Receives Non-Compliance Notice for Semaglutide Injection in Canada

Dr Reddy’s Laboratories ( (RDY) ) has shared an update.

On October 29, 2025, Dr. Reddy’s Laboratories received a Notice of Non-Compliance from the Pharmaceutical Drugs Directorate in Canada concerning their Abbreviated New Drug Submission for Semaglutide Injection. The notice requests additional information and clarifications, which the company plans to address promptly. Despite this setback, Dr. Reddy’s remains confident in the quality and safety of their product and is committed to making it available in Canada and other markets as soon as possible. The company appreciates the support of its stakeholders and will provide further updates when appropriate.

The most recent analyst rating on (RDY) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories scores well due to strong financial performance and strategic growth initiatives. However, technical indicators suggest caution due to potential overbought conditions, and valuation metrics indicate moderate pricing. Earnings call insights reveal mixed sentiment, with growth opportunities balanced by regulatory challenges.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a prominent pharmaceutical company based in Hyderabad, India. The company specializes in the development and production of generic medications, active pharmaceutical ingredients, and biosimilars, with a focus on making affordable healthcare accessible globally.

Average Trading Volume: 1,057,215

Technical Sentiment Signal: Strong Buy

Current Market Cap: $12.2B

For detailed information about RDY stock, go to TipRanks’ Stock Analysis page.